Abstracts tagged "giant cell arteritis"

Abstract Number: 2360 • 2012 ACR/ARHP Annual Meeting
Prevalence, Management and Outcomes of PET Positive Large Vessel Vasculitis in Difficult to Treat PMR and GCA Patients
Pravin Patil¹, Shaifali Jain², Katerina Achilleos³, Tochukwu Adizie¹, Mark Williams¹, Matthew Tam² and Bhaskar Dasgupta⁴, ¹Rheumatology, Southend University Hospital, Westcliff on sea, United Kingdom, ²Radiology, Southend University Hospital, Westcliff on sea, United Kingdom, ³Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom, ⁴Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom
Background/Purpose: Management of PMR and GCA can be challenging in patients with persistently elevated inflammatory markers, prominent constitutional symptoms and inadequate steroid response. We undertook…
Abstract Number: 859 • 2012 ACR/ARHP Annual Meeting
Endothelin-1 (ET-1) Induces Extracellular Matrix Protein Production by Human Temporal Artery Derived Myointimal Cells. A Mechanism Potentially Leading to Intimal Hyperplasia and Vascular Occlusion in Giant-Cell Arteritis
Ester Planas-Rigol¹, Marc Corbera-Bellalta², Marco A. Alba³, Itziar Tabera-Bahillo³, Sergio Prieto-Gonzalez³, Georgina espigol-Frigole³, Jose Hernandez-Rodriguez⁴, Ester Lozano⁵ and Maria C. Cid⁶, ¹Systemic Autoimmune Diseases, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Hospital Clinic University Barcelona, Hospital Clinic University Barcelona, Barcelona, Spain, ³Vasculitis research Unit, systemic autoimmune diseases department. Idibaps., Hospital Clinic University Barcelona, Barcelona, Spain, ⁴Vasculitis research Unit, systemic autoimmune diseases department. Idibaps., Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁵Vasculitis research Unit, systemic autoimmune diseases department. Idibaps., Hospital Clinic University Barcelona, ⁶Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Endothelin-1 (ET-1) is the main isoform of the Endothelin family. It is also the most powerful vasoconstrictor identified. ET-1 is constitutively produced in blood…
Abstract Number: 2568 • 2012 ACR/ARHP Annual Meeting
The Risk of Pulmonary Embolism and Deep Vein Thrombosis in Giant Cell Arteritis: A Population-Based Cohort Study
J. Antonio Avina-Zubieta¹, Diane Lacaille², Eric C. Sayre³, Jacek A. Kopec³ and Hyon Choi⁴, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Rheumatology, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Arthritis Research Centre of Canada/University of British Columbia, Boston, MA
Background/Purpose: A recent hospital-based study has suggested an 8 fold increased risk of pulmonary embolism (PE) in individuals with polymyalgia rheumatica in the year following…
Abstract Number: 2390 • 2012 ACR/ARHP Annual Meeting
Color Doppler Ultrasonography an Alternative to CT/MR Angiography for Identifying Large Vessel Involvement in Giant Cell Arteritis?
Andreas P. Diamantopoulos¹, Glenn Haugeberg¹ and Geirmund Myklebust², ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Rheumatology, Hospital of Southern Norway, Kristiansand, Norway
Background/Purpose: Large vessel involvement has been reported to be present in 20-50% of patients with giant cell arteritis (GCA). Computed tomography (CT) and magnetic resonance…
Abstract Number: 2350 • 2012 ACR/ARHP Annual Meeting
Similarities Exceeds Differences in the Pattern of Joint and Vascular Positron Emission/Computed Tomography Uptake in Polymyalgia Rheumatica and Giant Cell Arteritis
Dario Camellino¹, Silvia Morbelli², Francesco Paparo³, Michela Massollo², Gianmario Sambuceti⁴ and Marco A. Cimmino⁵, ¹Dipartimento Medicina Interna, Clinica Reumatologica, Genova, Italy, ²Dipartimento Medicina Interna, Medicina Nucleare, Genova, Italy, ³Radiology Unit, E.O. Ospedali Galliera, Genoa, Italy, ⁴Dipartimento di Medicina Interna, Medicina Nucleare, Genova, Italy, ⁵Department of Internal Medicine, Academic Unit of Clinical Rheumatology, University of Genova, Genova, Italy
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are two frequent overlapping diseases. The purpose of this work is to examine the relationship between…
Abstract Number: 2353 • 2012 ACR/ARHP Annual Meeting
TLR2 Activation by Acute Serum Amyloid A Induces Pro-Inflammatory Mechanisms in a Novel Ex Vivo Temporal Artery Explant Culture/Model of Giant Cell Arteritis
Peadar Rooney¹, Danielle Molloy¹, Jennifer McCormick², Mary Connolly¹, Sinead M. Miggin³, Ashwini Maratha³, Douglas J. Veale⁴, Conor Murphy⁵, Eamonn Molloy⁶ and Ursula Fearon⁷, ¹Rheumatology, Dublin Academic Medical Centre, Dublin, Ireland, ²Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ³Biology, Immune Signalling Laboratory, Maynooth, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁵Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁶Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁷Rheumatology, Translation Research Group, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) is the most common form of primary vasculitis. The pathogenesis of this disease is characterised by disregulated angiogenesis and inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].